Jafron Biomedical Co (SZSE:300529) Total Current Assets : ¥3,599 Mil (As of Mar. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Jafron Biomedical Co Total Current Assets?

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. Jafron Biomedical Co's total current assets for the quarter that ended in Mar. 2024 was ¥3,599 Mil.

Jafron Biomedical Co Total Current Assets Historical Data

The historical data trend for Jafron Biomedical Co's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Jafron Biomedical Co Total Current Assets Chart

Jafron Biomedical Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Current Assets

Get a 7-Day Free Trial

1,559.74

1,986.61

3,055.65

3,293.25

3,311.84

Jafron Biomedical Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Current Assets	Get a 7-Day Free Trial															3,835.56	3,490.88	3,336.27	3,311.84	3,599.00

Jafron Biomedical Co Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

Jafron Biomedical Co's Total Current Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	2810.294	+	87.723	+	384.996	+	28.829
	=	3,312

Jafron Biomedical Co's Total Current Assets for the quarter that ended in Mar. 2024 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	3139.268	+	107.832	+	320.899	+	31.005
	=	3,599

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Jafron Biomedical Co (SZSE:300529) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

Jafron Biomedical Co's Liquidation Value for the quarter that ended in Mar. 2024 is

	Liquidation value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	3139.268	-	2620.019	+	0.75 * 48.545	+	0.5 * 320.899
=	716

Jafron Biomedical Co Total Current Assets Related Terms

Thank you for viewing the detailed overview of Jafron Biomedical Co's Total Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Jafron Biomedical Co (SZSE:300529) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Jafron Biomedical Co Ltd (SZSE:300529) » Definitions » Total Current Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 98, Science and Technology 6th Road, High-tech Zone, Guangdong Province, Zhuhai, CHN, 519085

Website

http://www.jafron.com

Jafron Biomedical Co Ltd is a China-based company engaged in the research, development, production, and sales of biomaterials and medical devices. It offers solutions for kidney disease, poisoning, rheumatic immune solution, critical illness and liver disease. The company's products include JFYC-100 pre-punching machine, DX-10 blood purifier, and HA resin hemoperfusion.

Executives

Li Feng	Director
He Xiao Lian	Executives
Dong Fan	Directors, Directors, and Executives
Ceng Kai	Directors, executives
Tang Xian Min	Directors, executives
Zhang Ming Yuan	Secretary Dong
Fang Li Hua	Supervisors
Zhang Guang Hai	Directors, executives
Li De Zhi	Executives
Lu Shao Zhang	Executives

Jafron Biomedical Co (SZSE:300529) Headlines

No Headlines